This article was originally published on Microdose Psychedelic Insights and appears here with permission.
Anyone owning shroom stocks will know that the last few months have been a bumpy ride. Actually, more like a horrifying high-speed roller coaster hurtling in one direction — down.
The psychedelic medicine market has been taking a beating as of late, but despite this short-term pain the overall outlook continues to be strong. Clinical trials are advancing and positive studies and research continues to be released. Giving support to this positive macro trend is a recent report by CB Insights looking at the amount of capital funding going into new ventures in the psychedelic space.
The report states that funding to psychedelics startups continues to increase despite any short-term fluctuations. It’s …